Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease causing proteins, today announced the closing of a USD $7.5m Series A round, led by Advent Life Sciences. Seed round funders the Scottish Investment Bank, with backing from the Scottish Growth Scheme, and the European Investment Fund joined the round, along with...
The MRC-University of Glasgow Centre for Virus Research (CVR) is to play a key role in new COVID-19 scientific project, announced today (Monday 23 March). The project, which will be led by the University of Edinburgh with involvement from colleagues in Glasgow, Imperial College London, University College London and the University of Liverpool, has received £4.9m of rapid response government funding to tackle the coronavirus pandemic....
A project to grow the Tay Cities BioMedical cluster of world-class life sciences companies will generate hundreds of millions of pounds for the local economy and strengthen Scotland’s reputation as a centre of excellence, according to new economic analysis. The proposed Tay Cities Biomedical Cluster, led by the University of Dundee in partnership with NHS Tayside, has been earmarked for £25million in initial funding from...
Researchers at the University of Glasgow and NHSGGC are set to benefit from a £5million European research award to refocus research efforts on mesothelioma, an asbestos-related, incurable cancer. The award will support the UofG-led PREDICT-Meso (Pre-malignant drivers combined with target-drug validation in mesothelioma) project, which will establish an international network of researchers across the UK, Spain and Italy. Together, teams hope to better understand how...
Novel treatments that may reverse the effects of multiple sclerosis will be investigated by a new drug-discovery company spun out from the University of Edinburgh. Backed by Series A funding of £5 million over its first three years, Pheno Therapeutics will search for new drugs that aim to repair damage to the nervous system and significantly improve patients’ debilitating symptoms. Building on original research by...
Ubiquigent Limited (Ubiquigent) has announced the launch of an exciting new service as part of its Drug Discovery Screening Platform – DUBprofiler-Cell™. DUBprofiler-Cell™ supports the development of novel deubiquitylase (DUB) enzyme inhibitors by revealing the ‘active DUBome’ in a given cell-line or tissue (e.g. non-diseased and diseased), and by reporting the target engagement of test compounds to that ‘active DUBome’. The DUBprofiler-Cell™ assay utilises activity-based probes...